Word

RNAGADE

Status

Pending

Status Code

731

Status Date

Tuesday, April 9, 2024

Serial Number

90545040

Mark Type

4000

Filing Date

Wednesday, February 24, 2021

Published for Opposition

Tuesday, March 14, 2023

Trademark Owner History

Renagade Therapeutics LLC - Owner At Publication

Classifications

5 Pharmaceutical preparations and substances, namely, RNA and DNA therapeutics for the treatment of infectious diseases, blood disorders, sepsis, alopecia, and cognitive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of osteoporosis; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, RNA and DNA therapeutics for treating diabetes; pharmaceutical preparations, namely, RNA and DNA therapeutics for use in chemotherapy; pharmaceutical preparations, namely, RNA and DNA therapeutics for cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; pharmaceutical preparations, namely, antivirals; therapeutic pharmaceuticals, namely, RNA and DNA therapeutics for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; vaccine preparations, namely, RNA and DNA vaccine preparations; vaccines, namely, RNA and DNA vaccines; anti-epileptic pharmaceutical preparations; human vaccine preparations, namely, RNA and DNA vaccine preparations; medical preparations for the treatment of cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders, infectious disorders, and reproductive disorders; medicinal preparations for the treatment of infectious diseases and for use in oncology; mixed biological preparations, namely, RNA and DNA therapeutics for the prevention and treatment of infectious diseases; pharmaceutical preparations, namely, RNA and DNA therapeutics for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of joint disease; pharmaceutical products, namely, RNA and DNA therapeutics for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic vaccines, namely, RNA and DNA therapeutics; all of the foregoing excluding medicinal dietary and nutritional supplements

RENAGADE RENEGADE

Trademark Events

Apr 10, 2024

Notice Of Approval Of Extension Request E-Mailed

Apr 9, 2024

Sou Extension 2 Granted

Apr 9, 2024

Sou Extension 2 Filed

Apr 9, 2024

Sou Teas Extension Received

Feb 20, 2024

Teas Withdrawal Of Attorney Received-Firm Retains

Feb 20, 2024

Teas Change Of Correspondence Received

Feb 20, 2024

Attorney/Dom.Rep.Revoked And/Or Appointed

Feb 20, 2024

Teas Revoke/App/Change Addr Of Atty/Dom Rep Received

Oct 24, 2023

Notice Of Approval Of Extension Request E-Mailed

Oct 20, 2023

Sou Extension 1 Granted

Oct 20, 2023

Sou Extension 1 Filed

Oct 20, 2023

Sou Teas Extension Received

May 9, 2023

Noa E-Mailed - Sou Required From Applicant

Mar 14, 2023

Official Gazette Publication Confirmation E-Mailed

Mar 14, 2023

Published For Opposition

Feb 22, 2023

Notification Of Notice Of Publication E-Mailed

Feb 7, 2023

Approved For Pub - Principal Register

Jan 4, 2023

Teas/Email Correspondence Entered

Jan 4, 2023

Correspondence Received In Law Office

Jan 4, 2023

Teas Request For Reconsideration Received

Jan 4, 2023

Jurisdiction Restored To Examining Attorney

Aug 22, 2022

Notification Of Action Denying Req For Recon E-Mailed

Aug 22, 2022

Action Denying Req For Recon E-Mailed

Aug 22, 2022

Action Continuing Final - Completed

Aug 20, 2022

Teas/Email Correspondence Entered

Aug 20, 2022

Correspondence Received In Law Office

Aug 20, 2022

Assigned To Lie

Jul 26, 2022

Teas Request For Reconsideration Received

Jul 26, 2022

Ex Parte Appeal-Instituted

Jul 26, 2022

Jurisdiction Restored To Examining Attorney

Jul 26, 2022

Exparte Appeal Received At Ttab

Jan 26, 2022

Notification Of Final Refusal Emailed

Jan 26, 2022

Final Refusal E-Mailed

Jan 26, 2022

Final Refusal Written

Dec 27, 2021

Teas/Email Correspondence Entered

Dec 26, 2021

Correspondence Received In Law Office

Dec 26, 2021

Teas Response To Office Action Received

Sep 15, 2021

Notification Of Non-Final Action E-Mailed

Sep 15, 2021

Non-Final Action E-Mailed

Sep 15, 2021

Non-Final Action Written

Sep 15, 2021

Assigned To Examiner

May 26, 2021

New Application Office Supplied Data Entered

Feb 27, 2021

New Application Entered